Today Lincor announced general availability of MediaLINC – its innovative Android-based Patient Engagement solution that delivers a range of education, entertainment and clinical content direct to standard HD TV sets. “Lincor has already been phenomenally successful in defining point of care patient engagement to bedside…
Category: News
Novel Human Tissue Samples Available For Research and Development
Human tissues are extensively employed by pharmaceutical and academic researchers to identify and validate new biomarkers and drug discovery targets. Such tissues are also widely used to study the efficacy, reproducibility, and safety of experimental drug candidates against unmet clinical needs. “This collaboration will open…
Medtronic Announces Preliminary Outcomes for World’s Smallest Cardiac Pacemaker
Medtronic announces preliminary results from the first human implants of the world’s smallest pacemaker, the Micra Transcatheter Pacing System (TPS). Results from the first four patients to receive the Micra TPS were reported at CARDIOSTIM / EHRA EUROPACE 2014, World Congress in Electrophysiology and Cardiac…
Bayer receives green light for new long-term contraceptive in the EU
Bayer HealthCare has successfully concluded the European registration procedure for its new low dose levonorgestrel-releasing intrauterine system (IUS). This long-term contraceptive is placed in the uterus for the prevention of pregnancy for up to three years. Sweden served as Reference Member State for the Decentralized…
Boston Scientific Defibrillators Receive CE Mark for Extended Longevity
Boston Scientific Corporation has received CE Mark approval for increased longevity projections for the INCEPTA™, ENERGEN™, PUNCTUA™, COGNIS® and TELIGEN® implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds). The longevity projections are based on data submitted to the European authorities and vary for each…
ELIQUIS (apixaban) Approved in Europe for Prevention of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation
Bristol-Myers Squibb and Pfizer announced today that the European Commission has approved ELIQUIS (apixaban) for prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors. ELIQUIS is the only oral anticoagulant that has demonstrated superior risk…
Xarelto: FDA approves Xarelto used to reduce risk of blood clots after hip and Knee Surgery
The U.S. Food and Drug Administration approved a medicine, Xarelto to decrease the possibility of blood clotting, pulmonary embolism (PE) and deep vein thrombosis (DVT) after knee or hip surgery for replacement.
Type 2 Diabetes:FDA approves new treatment for Type 2 diabetes
The U.S FDA approved a new treatment for type 2 diabetes. This treatment for type 2 diabetes is a Tradjenta (linagliptin) tablets. This treatment is to be down with a diet and exercise plan, which improves the blood sugar control in person who has type…